Transferon™, a peptide mixture with immunomodulatory properties is not immunogenic when administered with various adjuvants

Published on Jul 14, 2017in Journal of Immunotoxicology2.974
· DOI :10.1080/1547691X.2017.1346009
Sandra Avila2
Estimated H-index: 2
(IPN: Instituto Politécnico Nacional),
Leslie Muñoz-García3
Estimated H-index: 3
(IPN: Instituto Politécnico Nacional)
+ 8 AuthorsSonia Mayra Pérez-Tapia11
Estimated H-index: 11
(IPN: Instituto Politécnico Nacional)
AbstractTransferon, a human dialyzable leukocyte extract (hDLE), is a biotherapeutic that comprises a complex mixture of low-molecular-weight peptides (< 10 kDa) and is used to treat diseases with an inflammatory component. Some biotherapeutics, including those composed of peptides, can induce anti-drug antibodies (ADA) that block or diminish their therapeutic effect. Nevertheless, few studies have evaluated peptide-derived drug immunogenicity. In this study, the immunogenicity of Transferon was examined in a murine model during an immunization scheme using the following adjuvants: Al(OH)3, incomplete Freund's adjuvant (IFA), or Titermax Gold. The inoculation scheme entailed three routes of administration (intraperitoneal, Day 1; subcutaneous, Day 7; and intramuscular, Day 14) using 200 μg Transferon/inoculation. Serum samples were collected on Day 21. Total IgG levels were quantitated by affinity chromatography, and specific antibodies against components of Transferon were analyzed by dot-blot and ELISA....
📖 Papers frequently viewed together
37 Citations
48 Citations
40 Citations
#1Sandra Scheiblhofer (University of Salzburg)H-Index: 30
#2Josef Laimer (University of Salzburg)H-Index: 6
Last. Josef Thalhamer (University of Salzburg)H-Index: 40
view all 5 authors...
ABSTRACTIntroduction: In modern vaccinology and immunotherapy, recombinant proteins more and more replace whole organisms to induce protective or curative immune responses. Structural stability of proteins is of crucial importance for efficient presentation of antigenic peptides on MHC, which plays a decisive role for triggering strong immune reactions.Areas covered: In this review, we discuss structural stability as a key factor for modulating the potency of recombinant vaccines and its importa...
59 CitationsSource
#1Larisa C. Wu (CDER: Center for Drug Evaluation and Research)H-Index: 1
#2Fu Chen (CDER: Center for Drug Evaluation and Research)H-Index: 12
Last. Lawrence X. Yu (CDER: Center for Drug Evaluation and Research)H-Index: 57
view all 5 authors...
Abstract Peptides are a fast growing segment in the pharmaceutical industry. Consequently, the industry and regulatory agencies are increasing their focus on the regulatory path and quality considerations for peptide development and manufacturing. Although most peptides are synthetic, manufactured by solid phase synthesis, nevertheless they are complex molecules with challenging quality and regulatory aspects. This paper provides a structured overview of relevant quality issues for chemically sy...
15 CitationsSource
#1Tapasa Kumar Sahoo (Sambalpur University)H-Index: 5
#2Prasant Kumar Jena (UC Davis: University of California, Davis)H-Index: 19
Last. Sriram Seshadri (NU: Nirma University of Science and Technology)H-Index: 13
view all 6 authors...
Bacteriocin TSU4 is a novel antimicrobial peptide isolated from Catla catla gut isolate Lactobacillus animalis TSU4. It has been reported for its potential antimicrobial activity against fish pathogens and food spoilage bacteria. In vivo safety evaluation is necessary to determine its immunogenicity, toxicity, and importance in real-life applications. The present study was designed to evaluate the immunogenicity, acute and sub-chronic toxicity of bacteriocin TSU4 in BALB/c mice to ensure its saf...
11 CitationsSource
#1Emilio Medina-Rivero (IPN: Instituto Politécnico Nacional)H-Index: 11
#2Luis Vallejo-Castillo (IPN: Instituto Politécnico Nacional)H-Index: 7
Last. Sonia Mayra Pérez-Tapia (IPN: Instituto Politécnico Nacional)H-Index: 11
view all 9 authors...
Transferon, a biotherapeutic agent that has been used for the past 2 decades for diseases with an inflammatory component, has been approved by regulatory authorities in Mexico (COFEPRIS) for the treatment of patients with herpes infection. The active pharmaceutical ingredient (API) of Transferon is based on polydispersion of peptides that have been extracted from lysed human leukocytes by a dialysis process and a subsequent ultrafiltration step to select molecules below 10 kDa. To physicochemica...
10 CitationsSource
#1Juliana de Souza Apostólico (UNIFESP: Federal University of São Paulo)H-Index: 7
#2Victória Alves Santos Lunardelli (UNIFESP: Federal University of São Paulo)H-Index: 4
Last. Daniela Santoro Rosa (UNIFESP: Federal University of São Paulo)H-Index: 18
view all 5 authors...
Vaccination is one of the most efficient strategies for the prevention of infectious diseases. Although safer, subunit vaccines are poorly immunogenic and for this reason the use of adjuvants is strongly recommended. Since their discovery in the beginning of the 20th century, adjuvants have been used to improve immune responses that ultimately lead to protection against disease. The choice of the adjuvant is of utmost importance as it can stimulate protective immunity. Their mechanisms of action...
133 CitationsSource
Chronic inflammatory diseases are now treated with a range of different biopharmaceuticals, often requiring lifelong parenteral administrations. This exposure to drugs is unnatural and can trigger the immune system and result in the formation of antidrug antibodies. Drug-specific antibodies will, if of sufficiently high titre and affinity, block the intended effect of the drug, increase its clearance and make continued treatment worthless. We expect the immune system to react towards therapies a...
8 CitationsSource
Human dialyzable leukocyte extracts (DLEs) are heterogeneous mixtures of low-molecular-weight peptides that are released on disruption of peripheral blood leukocytes from healthy donors. DLEs improve clinical responses in infections, allergies, cancer, and immunodeficiencies. Transferon is a human DLE that has been registered as a hemoderivate by Mexican health authorities and commercialized nationally. To develop an animal model that could be used routinely as a quality control assay for Transf...
12 CitationsSource
#1Daan J.A. Crommelin (UU: Utrecht University)H-Index: 90
Last. Stefan Mühlebach (University of Basel)H-Index: 23
view all 3 authors...
In the first chapter of this book the concept of non-biological complex drugs (NBCDs) is introduced. These are complex drug products but don’t fall in the category of ‘biologicals’. NBCDs were earlier defined as: medicinal products, not being a biological medicine, where the active substance is not a homo-molecular structure, but consists of different (closely related and often nanoparticulate) structures that cannot be isolated and fully quantitated, characterized and/or described by physicoche...
7 CitationsSource
#1Uriel García-Hernández (IPN: Instituto Politécnico Nacional)H-Index: 1
#2Frank Robledo-Avila (IPN: Instituto Politécnico Nacional)H-Index: 10
Last. Rommel Chacón-Salinas (IPN: Instituto Politécnico Nacional)H-Index: 17
view all 11 authors...
Dialyzable leukocyte extracts (DLE) transfer specific cell-mediated immune responses from sensitized donors to non-immune recipients. In addition, DLE have several immunomodulatory effects and are ...
16 CitationsSource
#1Emilio Medina-Rivero (IPN: Instituto Politécnico Nacional)H-Index: 11
#2Giovanna Merchand-Reyes (IPN: Instituto Politécnico Nacional)H-Index: 2
Last. Sonia Mayra Pérez-TapiaH-Index: 11
view all 9 authors...
Abstract Human dialyzable leukocyte extracts (DLEs) are heterogeneous mixtures of low-molecular-weight peptides that modulate immune responses in various diseases. Due their complexity, standardized methods to identify their physicochemical properties and determine that production batches are biologically active must be established. We aimed to develop and validate a size exclusion ultra performance chromatographic (SE-UPLC) method to characterize Transferon™, a DLE that is produced under good m...
27 CitationsSource
Cited By3
#1Gabriela Mellado-Sánchez (IPN: Instituto Politécnico Nacional)H-Index: 8
#2Juan José Lázaro-Rodríguez (IPN: Instituto Politécnico Nacional)H-Index: 1
Last. Sonia Mayra Pérez-Tapia (IPN: Instituto Politécnico Nacional)H-Index: 11
view all 11 authors...
Transferon® is an immunomodulator made of a complex mixture of peptides from human dialyzable leucocyte extracts (hDLEs). Development of surrogate antibodies directed to hDLE is an indispensable tool for studies during process control and preclinical trials. These antibodies are fundamental for different analytical approaches, such as identity test and drug quantitation, as well as to characterize its pharmacokinetic and mechanisms of action. A previous murine study showed the inability of the p...
1 CitationsSource
#1Alexis Jiménez-Uribe (IPN: Instituto Politécnico Nacional)H-Index: 2
#2Hugo Valencia-Martínez (IPN: Instituto Politécnico Nacional)H-Index: 1
Last. Sonia Mayra Pérez-Tapia (IPN: Instituto Politécnico Nacional)H-Index: 11
view all 11 authors...
Transferon® is a complex drug based on a mixture of low molecular weight peptides. This biotherapeutic is employed as a coadjuvant in clinical trials of several diseases, including viral infections and allergies. Given that macrophages play key roles in pathogen recognition, phagocytosis, processing, and antigen presentation, we evaluated the effect of Transferon® on phenotype and function of macrophage-like cells derived from THP-1 monocytes. We determined the surface expression of CD80 and CD8...
7 CitationsSource
#1Lu Yanzhi (Fourth Military Medical University)H-Index: 2
#2Jian Kang (Fourth Military Medical University)H-Index: 4
Last. Yinlan Bai (Fourth Military Medical University)H-Index: 6
view all 9 authors...
Abstract Tuberculosis is chronic infectious disease caused by Mycobacterium tuberculosis ( M.tb ) that is prevalent worldwide. Several specific antigens, such as Antigen 85B (Ag85B) and 6 kDa early secretory antigenic target (ESAT-6) protein of M.tb , are listed as some of the candidate subunit vaccines against M.tb . ESAT-6, as a virulent factor and differential gene in M.tb , shows insufficient immunogenicity in animal model. In order to investigate the ways to improve the immunogenicity of ES...
7 CitationsSource